US 11,944,625 B2
Calmodulin inhibitors, Chk2 inhibitors and RSK inhibitors for the treatment of ribosomal disorders and ribosomapathies
James Bradner, Weston, MA (US); Jun Qi, Sharon, MA (US); Dennis Buckley, Cambridge, MA (US); Leonard I. Zon, Brookline, MA (US); and Elizabeth Macari, Wilmington, MA (US)
Assigned to THE CHILDREN'S MEDICAL CENTER CORPORATION, Boston, MA (US); and DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US)
Filed by THE CHILDREN'S MEDICAL CENTER CORPORATION, Boston, MA (US); and DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US)
Filed on Feb. 12, 2021, as Appl. No. 17/175,079.
Application 17/175,079 is a continuation of application No. 16/315,899, granted, now 10,980,808, previously published as PCT/US2017/041851, filed on Jul. 13, 2017.
Claims priority of provisional application 62/361,631, filed on Jul. 13, 2016.
Prior Publication US 2022/0008420 A1, Jan. 13, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/517 (2006.01); A61K 31/225 (2006.01); A61K 31/403 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/5415 (2006.01); A61K 31/55 (2006.01); A61K 31/7048 (2006.01); A61K 45/06 (2006.01); A61P 7/06 (2006.01)
CPC A61K 31/517 (2013.01) [A61K 31/225 (2013.01); A61K 31/403 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/5415 (2013.01); A61K 31/55 (2013.01); A61K 31/7048 (2013.01); A61P 7/06 (2018.01); A61K 45/06 (2013.01)] 17 Claims
 
1. A phenothiazine compound of Formula (I):

OG Complex Work Unit Chemistry
wherein:
X is O or S;
R1 is H, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, pentyl, neopentyl, hexyl, alkenyl, alkynyl, cyclyl, heterocyclyls, acyl, aryl, heteroaryl, alkylheteroaryl or alkylaryl;
each R is independently H, halo, alkyl, alkenyl, alkynyl, haloalkyl, CN, OH, NH2, alkylamino, dialkylamino, CO2H, acyl, SH, thioalkoxy, SO2H, or SO3H; or a pharmaceutically acceptable salt thereof.